AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Harrison, New York.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:AITB
Previous Symbol
CUSIPN/A
Phone972-8684-3313
Debt
Debt-to-Equity RatioN/A
Current Ratio4.03
Quick Ratio4.03
Price-To-Earnings
Trailing P/E Ratio-1.35
Forward P/E Ratio-4.26
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)($3.01)
Net Income$-18,040,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-168.23%
Miscellaneous
Employees12
Outstanding Shares8,530,000
Market Cap$34.56 million
OptionableNot Optionable
AIT Therapeutics (OTCMKTS:AITB) Frequently Asked Questions
What is AIT Therapeutics' stock symbol?
AIT Therapeutics trades on the OTCMKTS under the ticker symbol "AITB."
How were AIT Therapeutics' earnings last quarter?
AIT Therapeutics Inc (OTCMKTS:AITB) issued its quarterly earnings data on Wednesday, November, 14th. The company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.32. View AIT Therapeutics' Earnings History.
When is AIT Therapeutics' next earnings date?
Has AIT Therapeutics been receiving favorable news coverage?
News stories about AITB stock have trended somewhat positive this week, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. AIT Therapeutics earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are some of AIT Therapeutics' key competitors?
Some companies that are related to AIT Therapeutics include Alphatec (ATEC), RA Medical Systems (RMED), Sensus Healthcare (SRTS), Arch Therapeutics (ARTH), Apollo Endosurgery (APEN), STRATA Skin Sciences (SSKN), Invo Bioscience (IVOB), Endologix (ELGX), iCAD (ICAD), Repro-Med Systems (REPR), Pro-Dex (PDEX), Motus GI (MOTS), CAS Medical Systems (CASM), SANUWAVE Health (SNWV) and Spectral Medical (EDTXF).
Who are AIT Therapeutics' key executives?
AIT Therapeutics' management team includes the folowing people:
- Mr. Steven Adam Lisi, CEO & Chairman (Age 47)
- Mr. Amir Avniel, Co-Founder, Pres, COO & Director (Age 44)
- Mr. Douglas J. Beck, Chief Financial Officer (Age 57)
- Prof. Asher Tal M.D., Sr. VP of Clinical Research & Member of Scientific Advisory Board
- Dr. Giora Davidai M.D., Chief Medical Officer
How do I buy shares of AIT Therapeutics?
Shares of AITB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AIT Therapeutics' stock price today?
One share of AITB stock can currently be purchased for approximately $4.05.
How big of a company is AIT Therapeutics?
AIT Therapeutics has a market capitalization of $34.56 million. The company earns $-18,040,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. AIT Therapeutics employs 12 workers across the globe.
What is AIT Therapeutics' official website?
How can I contact AIT Therapeutics?
AIT Therapeutics' mailing address is 2 ILAN RAMON SCIENCE PARK, NESS ZIONA L3, 7403635. The company can be reached via phone at 972-8684-3313.
MarketBeat Community Rating for AIT Therapeutics (OTCMKTS AITB)
MarketBeat's community ratings are surveys of what our community members think about AIT Therapeutics and other stocks. Vote "Outperform" if you believe AITB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AITB will underperform the S&P 500 over the long term. You may vote once every thirty days.
